Galapagos (NL:LKFT)
:LKFT
Want to see NL:LKFT full AI Analyst Report?
Top Page
Galapagos
(LKFT)
Select Model
Select Model
Rating:62Neutral
Price Target:
€25.00
▲(1.21% Upside)
Action:Downgraded
Date:05/09/26
The score is primarily supported by strong solvency and improved profitability, but is held back by ongoing negative operating/free cash flow and a weak technical backdrop (below key moving averages with negative MACD). Valuation offers only moderate support given the ~29.8 P/E and no dividend yield data.
Positive Factors
Conservative balance sheet
Very low leverage and high solvency provide durable financial flexibility, allowing Galapagos to fund R&D and pursue partnerships without urgent refinancing. Improved returns on equity (~16% TTM) show the company can generate meaningful earnings from its capital base, reducing long-term solvency risk.
Negative Factors
Persistent cash burn
Consistent negative OCF and FCF indicate the business is not self-funding and depends on reserves or external financing. Persistent cash burn limits strategic optionality, increases the chance of dilutive capital raises or reduced R&D scope, and is a material medium-term constraint on growth execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Very low leverage and high solvency provide durable financial flexibility, allowing Galapagos to fund R&D and pursue partnerships without urgent refinancing. Improved returns on equity (~16% TTM) show the company can generate meaningful earnings from its capital base, reducing long-term solvency risk.
Read all positive factors
Galapagos (LKFT) vs. iShares MSCI Netherlands ETF (EWN)
Market Cap
€1.57B
Dividend YieldN/A
Average Volume (3M)132.01K
Price to Earnings (P/E)29.8
Beta (1Y)0.71
Revenue Growth262.17%
EPS GrowthN/A
CountryNL
Employees704
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)7.39
Shares Outstanding65,897,070
10 Day Avg. Volume76,560
30 Day Avg. Volume132,014
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.57
Price to Sales (P/S)1.66
P/FCF Ratio-8.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€25.85Price Target Upside4.66% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering4
EPS Forecast (FY)-2.64
Revenue Forecast (FY)€33.64M
Galapagos Business Overview & Revenue Model
Company Description
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various pha...
How the Company Makes Money
Galapagos makes (or has made) money primarily through (1) collaboration and licensing arrangements with pharmaceutical partners—typically including upfront payments, research funding/reimbursements, development and regulatory milestone payments, s...
Galapagos Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
92
Very Positive
Cash Flow
34
Negative
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
Galapagos Technical Analysis
Negative
24.70
Price Trends
27.31
Negative
27.58
Negative
27.66
Negative
Market Momentum
-0.90
Positive
37.03
Neutral
40.06
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NL:LKFT, the sentiment is Negative. The current price of 24.7 is below the 20-day moving average (MA) of 25.58, below the 50-day MA of 27.31, and below the 200-day MA of 27.66, indicating a bearish trend. The MACD of -0.90 indicates Positive momentum. The RSI at 37.03 is Neutral, neither overbought nor oversold. The STOCH value of 40.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NL:LKFT.
Galapagos Peers Comparison
UnderperformOutperform
Sector (55)
NL:LKFT
Galapagos
23.78
-0.62
-2.54%
NL:PHARM
Pharming Group
1.13
0.27
31.97%
NL:VVY
Vivoryon Therapeutics AG
1.28
-0.45
-26.04%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.